Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Ping Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7006-4312; OpenAlex author ID A5100435536. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

  1. Migrasome-related LncRNA features predict immune microenvironment and prognosis in pancreatic cancer. Last author DOI 10.1038/s41598-025-24226-x↗
  2. Immune landscape and prognostic index for pancreatic cancer based on TCGA database and in vivo validation. Co-author DOI 10.1186/s12885-023-10597-9↗
  3. Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation. Last author DOI 10.1016/j.jep.2021.114691↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Panling Xu · 3 shared papers, 2022–2025 · strength 0.73
  2. Chien‐shan Cheng · 2 shared papers, 2022–2023 · strength 0.42
  3. Wenhao Li · 1 shared paper, 2025 · strength 0.30
  4. Shu Dong · 1 shared paper, 2023 · strength 0.24
  5. Zhen Chen · 1 shared paper, 2022 · strength 0.19
  6. Hao Chen · 1 shared paper, 2022 · strength 0.19
  7. Juying Jiao · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.